Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

Clinical trial NCT05088057 · UNKNOWN

Trial details

NCT number: NCT05088057
Sponsor: Aiping Shi
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Triple Negative Breast Cancer (TNBC)

Start date: 2021-09-20
Primary completion: 2024-08-19
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.